	US 11,795,223 B2
	Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
Yinuo Cao, Mountain View, CA (US); Mark Ping Chao, Mountain View, CA (US); Ravindra Majeti, Palo Alto, CA (US); Roy Louis Maute, Menlo Park, CA (US); Chris Hidemi Mizufune Takimoto, Menlo Park, CA (US); and Kelly Tran, East Palo Alto, CA (US)
Assigned to Forty Seven, Inc., Foster City, CA (US)
Filed by Forty Seven, Inc., Foster City, CA (US)
Filed on Oct. 16, 2020, as Appl. No. 17/72,681.
Claims priority of provisional application 63/031,438, filed on May 28, 2020.
Claims priority of provisional application 62/944,851, filed on Dec. 6, 2019.
Claims priority of provisional application 62/916,949, filed on Oct. 18, 2019.
Prior Publication US 2021/0115140 A1, Apr. 22, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 31/706 (2006.01); A61P 35/02 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2803 (2013.01) [A61K 31/706 (2013.01); A61P 35/02 (2018.01); C07K 16/2896 (2013.01); A61K 39/395 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01)]

12 Claims

1. A method of treating myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in a subject comprising:

a. determining or having determined the presence of at least one p53 mutation in the subject, before administering step;

b. selecting the subject that has at least one p53 mutation; and

c. administering to the subject (i) magrolimab and (ii) azacitidine;

thereby treating the subject.